DUPLICATION, MULTIDUPLICATION, AND AMPLIFICATION OF GENES ENCODING DRUG-METABOLIZING ENZYMES: EVOLUTIONARY, TOXICOLOGICAL, AND CLINICAL PHARMACOLOGICAL ASPECTS

This publication has 19 references indexed in Scilit:

• Ultrarapid metabolism of sparteine
  Pharmacogenetics, 1998
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
  Clinical Pharmacokinetics, 1997
• Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population*
  Clinical Pharmacology & Therapeutics, 1995
• Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
  Proceedings of the National Academy of Sciences, 1993
• Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population
  Pharmacogenetics, 1993
• Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
  The Lancet, 1993
• Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6
  Genomics, 1992
• Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese [letter]
  British Journal of Clinical Pharmacology, 1991
• DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE
  The Lancet, 1989
• Extremely Rapid Hydroxylation of Debrisoquine
  Therapeutic Drug Monitoring, 1985